Source: Annual Congress 2012 - Asthma and COPD at work: what are the effects of exposure and risk factors?
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Lavaud, G. Pfeiffer, P. Bonniaud, J.C. Dalphin, C. Leroyer, D. Muller, G. Mangiapan, F. de Blay (Reims, Metz, Dijon, Besançon, Brest, Montigny les Metz, Créteil, Strasbourg, France). Anti-IgE treatment: An alternative for severe allergic occupational asthma. Eur Respir J 2012; 40: Suppl. 56, 357

Member's Comments

No comment yet.

Related content which might interest you: Omalizumab, a novel therapy for severe allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001 Immunotherapy in severe asthma Source: ERS webinar 2021: Immunotherapy in severe asthma Year: 2021 Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Assesment of long-term omalizumab treatment in severe allergic asthma Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Refining asthma treatment for mild asthma Source: Virtual Congress 2020 – Rethinking asthma Year: 2020 Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2002; 20: 73-78 Year: 2002 Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009 Omalizumab in children with severe persistent allergic asthma Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Treatment of co-morbid allergic asthma and perennial allergic rhinitis with the anti-IgE agent omalizumab Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 Specific immunotherapy in the management of allergic asthma Source: Annual Congress 2008 - PG2 - Asthma: natural history, risk factors and overall management Year: 2008 Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy Source: Eur Respir Rev 2007; 16: 73-77 Year: 2007 Therapeutic approach in allergic asthma: ASIT oposit to ICS Source: Annual Congress 2010 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2010 Work-related asthma and occupational asthma: clinical approach Source: Annual Congress 2005 - Occupational asthma Year: 2005 Real-life long-term omalizumab therapy in children with severe allergic asthma Source: Eur Respir J 2015; 46: 856-859 Year: 2015 Endotypes of severe allergic asthma patients who clinically benefit from Anti-IgE therapy Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD Year: 2018 Systemic steroid use in children with allergic (IgE-mediated) asthma receiving omalizumab Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Anti-IgE treatment in children with severe intrinsic asthma Source: International Congress 2019 – Severe acute asthma and troublesome wheezing Year: 2019